Mount Sinai Health System Partners with SOPHiA GENETICS to Enhance Precision Cancer Care
Mount Sinai Health System, a leading academic health system in the United States, has announced a collaboration with SOPHiA GENETICS, a global leader in AI-driven precision medicine. This partnership aims to advance cancer research and enhance genomic testing capabilities using the AI-powered SOPHiA DDM™ Platform. Mount Sinai, which supports care for over 4,000 oncology patients annually, will leverage this platform to strengthen next-generation sequencing (NGS) capabilities for blood cancers and solid tumors. The SOPHiA DDM™ Platform is designed to detect and interpret complex genomic variants, improving operational efficiency by consolidating critical steps in the analysis pipeline and reducing manual interpretation time. This collaboration was announced at the American Association for Cancer Research® (AACR) Annual Meeting in San Diego. 
